{"id":20340,"date":"2023-10-04T08:28:20","date_gmt":"2023-10-04T06:28:20","guid":{"rendered":"https:\/\/ggba.swiss\/hes-so-valais-wallis-and-debiopharm-partner-up-to-battle-cancer\/"},"modified":"2023-10-04T08:32:10","modified_gmt":"2023-10-04T06:32:10","slug":"la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/","title":{"rendered":"La HES-SO Valais-Wallis et Debiopharm s&rsquo;associent pour lutter contre le cancer"},"content":{"rendered":"\n<p>L&rsquo;<a href=\"https:\/\/www.hevs.ch\/fr\/recherche-appliquee-et-developpement-a-la-hes-so-valais-wallis\/institut-technologies-du-vivant-valais\/\">Institut des Technologies du vivant<\/a> de la Haute \u00c9cole d\u2019Ing\u00e9nierie de la <a href=\"https:\/\/www.hevs.ch\/fr\">HES-SO Valais-Wallis<\/a> a conclu un contrat de collaboration de cinq ans avec <a href=\"https:\/\/www.debiopharm.com\/manufacturing-science\/\">Debiopharm Research &amp; Manufacturing<\/a> \u00e0 Martigny (canton du Valais) pour cr\u00e9er de nouvelles technologies cibl\u00e9es pour la vectorisation de fragments d&rsquo;anticorps. Financ\u00e9 \u00e0 hauteur de CHF 1.1 million par Debiopharm, avec un ajout potentiel de CHF 1 million suppl\u00e9mentaire, ce projet de recherche commun vise \u00e0 r\u00e9volutionner la pr\u00e9paration de conjugu\u00e9s de fragments d\u2019anticorps th\u00e9rapeutiques dans la lutte contre le cancer.<\/p>\n\n\n\n<p>Le projet de recherche commun pr\u00e9voit le d\u00e9veloppement de conjugu\u00e9s d&rsquo;anticorps (ADC), am\u00e9liorant leur efficacit\u00e9 gr\u00e2ce \u00e0 de nouvelles technologies de conjugaison qui associent un agent de ciblage \u00e0 une mol\u00e9cule th\u00e9rapeutique. Ceci offre des th\u00e9rapies cibl\u00e9es et puissantes prometteuses en oncologie. La nouvelle collaboration entre HES-SO et Debiopharm prolonge l&rsquo;accord fructueux initi\u00e9 en 2018, qui a abouti au d\u00e9veloppement de la technologie AbYlink. L\u2019am\u00e9lioration de cette technologie de conjugaison de mol\u00e9cules sera appliqu\u00e9e \u00e0 des applications th\u00e9rapeutiques et diagnostiques. Sous le label Debiolab 2.0, qui d\u00e9signera \u00e9galement le laboratoire d\u00e9di\u00e9 de la HES-SO Valais-Wallis, ce nouveau projet de recherche d\u00e9butera en novembre 2023 et s&rsquo;\u00e9tendra sur une p\u00e9riode de cinq ans. Le financement de CHF 1.1 million assur\u00e9 par Debiopharm couvrira les co\u00fbts de recherche pendant cette p\u00e9riode.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Un partenariat public-priv\u00e9 fructueux<\/h4>\n\n\n\n<p>Cette collaboration entre la HES-SO et Debiopharm marque la continuation d&rsquo;un partenariat public-priv\u00e9 fructueux qui dure depuis pr\u00e8s de 25 ans. \u00ab&nbsp;La collaboration scientifique entre Debiopharm et les chercheurs de la HES valaisanne est un bel exemple de partenariat public-priv\u00e9 r\u00e9ussi et de longue dur\u00e9e, qui se manifeste non seulement par une collaboration de recherche mais se prolonge \u00e9galement avec l\u2019engagement r\u00e9gulier par Debiopharm d\u2019ing\u00e9nieurs form\u00e9s \u00e0 la HES-SO&nbsp;\u00bb, a d\u00e9clar\u00e9 C\u00e9dric Sager, CEO de Debiopharm Research &amp; Manufacturing. Patrick Garrouste, Directeur ex\u00e9cutif de la recherche et du d\u00e9veloppement de Debiopharm Research &amp; Manufacturing, ajoute que la HES-SO Valais-Wallis, avec ses technologies innovantes de pointe et les connaissances sp\u00e9cialis\u00e9es associ\u00e9es, leur permettra d&rsquo;entrer dans une nouvelle dimension des th\u00e9rapies cibl\u00e9es avec ce partenariat.<\/p>\n\n\n\n<p>Orig\u00e8ne Nyanguile, responsable du groupe de recherche Peptide and Protein Technologies \u00e0 l&rsquo;Institut des Technologies du vivant, s\u2019est dit enthousiaste de continuer la collaboration avec Debiopharm afin d\u2019affiner les outils de conjugaison d\u2019anticorps th\u00e9rapeutiques \u00e9tablis depuis 2018.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La HES-SO Valais-Wallis et Debiopharm ont conclu un partenariat pour faire progresser la recherche sur la th\u00e9rapie cibl\u00e9e contre le cancer avec de nouveaux conjugu\u00e9s d&rsquo;anticorps.<\/p>\n","protected":false},"author":6,"featured_media":20334,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1162,1148,1140,1171,1142],"class_list":["post-20340","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-education-en-fr","tag-financing-fr-2","tag-oncology-fr-2","tag-pharma-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La HES-SO et Debiopharm s&#039;associent pour lutter contre le cancer<\/title>\n<meta name=\"description\" content=\"La HES-SO et Debiopharm ont conclu un partenariat pour faire avancer les th\u00e9rapies cibl\u00e9es contre le cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La HES-SO et Debiopharm s&#039;associent pour lutter contre le cancer\" \/>\n<meta property=\"og:description\" content=\"La HES-SO et Debiopharm ont conclu un partenariat pour faire avancer les th\u00e9rapies cibl\u00e9es contre le cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-04T06:28:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-04T06:32:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"La HES-SO Valais-Wallis et Debiopharm s&rsquo;associent pour lutter contre le cancer\",\"datePublished\":\"2023-10-04T06:28:20+00:00\",\"dateModified\":\"2023-10-04T06:32:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/\"},\"wordCount\":437,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Education\",\"Financing\",\"Oncology\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/\",\"name\":\"La HES-SO et Debiopharm s'associent pour lutter contre le cancer\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg\",\"datePublished\":\"2023-10-04T06:28:20+00:00\",\"dateModified\":\"2023-10-04T06:32:10+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"La HES-SO et Debiopharm ont conclu un partenariat pour faire avancer les th\u00e9rapies cibl\u00e9es contre le cancer.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"L\u2019Institut des Technologies du vivant de la Haute \u00c9cole d\u2019Ing\u00e9nierie de la HES-SO Valais-Wallis a scell\u00e9 une collaboration de cinq ans avec Debiopharm Research & Manufacturing pour innover dans les nouvelles technologies cibl\u00e9es de vectorisation de fragments d'anticorps. | \u00a9 HES-SO Valais-Wallis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La HES-SO Valais-Wallis et Debiopharm s&#8217;associent pour lutter contre le cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La HES-SO et Debiopharm s'associent pour lutter contre le cancer","description":"La HES-SO et Debiopharm ont conclu un partenariat pour faire avancer les th\u00e9rapies cibl\u00e9es contre le cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/","og_locale":"fr_FR","og_type":"article","og_title":"La HES-SO et Debiopharm s'associent pour lutter contre le cancer","og_description":"La HES-SO et Debiopharm ont conclu un partenariat pour faire avancer les th\u00e9rapies cibl\u00e9es contre le cancer.","og_url":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-10-04T06:28:20+00:00","article_modified_time":"2023-10-04T06:32:10+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"La HES-SO Valais-Wallis et Debiopharm s&rsquo;associent pour lutter contre le cancer","datePublished":"2023-10-04T06:28:20+00:00","dateModified":"2023-10-04T06:32:10+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/"},"wordCount":437,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg","keywords":["Biotech","Education","Financing","Oncology","Pharma","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/","url":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/","name":"La HES-SO et Debiopharm s'associent pour lutter contre le cancer","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg","datePublished":"2023-10-04T06:28:20+00:00","dateModified":"2023-10-04T06:32:10+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"La HES-SO et Debiopharm ont conclu un partenariat pour faire avancer les th\u00e9rapies cibl\u00e9es contre le cancer.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/HES-SO-Debiopharm-1180x811-1.jpg","width":1180,"height":811,"caption":"L\u2019Institut des Technologies du vivant de la Haute \u00c9cole d\u2019Ing\u00e9nierie de la HES-SO Valais-Wallis a scell\u00e9 une collaboration de cinq ans avec Debiopharm Research & Manufacturing pour innover dans les nouvelles technologies cibl\u00e9es de vectorisation de fragments d'anticorps. | \u00a9 HES-SO Valais-Wallis"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/la-hes-so-valais-wallis-et-debiopharm-sassocient-pour-lutter-contre-le-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"La HES-SO Valais-Wallis et Debiopharm s&#8217;associent pour lutter contre le cancer"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=20340"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20340\/revisions"}],"predecessor-version":[{"id":20342,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20340\/revisions\/20342"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/20334"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=20340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=20340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=20340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}